Acute kidney injury (AKI) has been recognized as a risk factor for the development of chronic kidney disease (CKD). Aldosterone has a critical role in promoting renal injury induced by ischemia. Here, we evaluated whether spironolactone administered before or after AKI caused by ischemia protects against CKD. In the first set of experiments, Wistar rats underwent a sham operation without or with prior spironolactone treatment, or underwent 45 minutes of bilateral renal ischemia without or with spironolactone treatment before ischemia and assessed over 270 days. The second set of rats received low (20 mg/kg) or high (80 mg/kg) doses of spironolactone at three different times after the sham operation or bilateral renal ischemia and were assessed after 90 days. Untreated animals developed CKD following ischemia-induced AKI as characterized by a progressive increase in proteinuria, renal dysfunction, podocyte injury, glomerular hypertrophy, and focal sclerosis. This was associated with increased oxidative stress, an upregulation of tumor growth factor (TGF)-b, followed by upregulation of the TGF-b downstream effectors phospho-Smad3, collagen I, fibronectin, and proinflammatory cytokines. Treatment with spironolactone either before or after ischemia prevented subsequent CKD by avoiding the activation of fibrotic and inflammatory pathways. Thus, spironolactone may be a promising treatment for the prevention of AKI-induced CKD. Kidney International (2012) 83, 93-103 b a s i c r e s e a r c h J Barrera-Chimal et al.: Spironolactone prevents CKD as a consequence of AKI 94 Kidney International (2012) 83, 93-103
Ischemic kidney injury is the primary cause of acute kidney injury (AKI) in hospitalized patients and is associated with high morbidity and mortality rates. In addition, the incidence of AKI has significantly increased in the past 15 years owing to an aging general population and the increased prevalence of obesity, diabetes, and hypertension, which predispose patients to an AKI event. [1] [2] [3] [4] [5] AKI occurs in approximately 15% of hospitalized patients and in up to 40-60% of intensive care unit patients. 6, 7 For many years, it was commonly thought that patients surviving episodes of AKI recover their renal function without further consequences. However, recent evidence based on epidemiological observations in patients who suffer from AKI strongly suggests otherwise. AKI has thus been proposed to be a risk factor for developing chronic kidney disease (CKD) and, in particular, for promoting the transition of CKD to end-stage renal disease. [8] [9] [10] [11] In support of this hypothesis, the probability of developing CKD or end-stage renal disease over time is proportional to the severity and duration of the AKI event. 8, 12, 13 Moreover, of great concern is the recent evidence demonstrating that 6.6% of AKI patients who had a complete renal function recovery exhibited a greater risk of death and de novo CKD after 2-4 years of follow-up. 12 Until now, however, the progression of AKI to CKD in rats with two intact kidneys, which would allow elucidating the mechanisms causing AKI to progress to CKD, has been rarely explored. Such a model would also be beneficial for identifying pharmacological interventions to prevent injury due to AKI and/or stop the development of CKD and end-stage renal disease.
Several studies involving experimental models have demonstrated that aldosterone has an important role in the physiopathology of renal injury induced by ischemic process, including acute and chronic cyclosporine A nephrotoxicity and ischemia/reperfusion (I/R). [14] [15] [16] [17] [18] [19] [20] [21] Accordingly, we have shown that prophylactic spironolactone treatment 16 or adrenal gland removal 17 completely prevents AKI in rats undergoing bilateral renal ischemia. Furthermore, spironolactone administration at different postischemia intervals prevents or reduces functional and structural renal injury, 22 suggesting that aldosterone is a key molecule in mediating ischemic renal injury and that mineralocorticoid receptor (MR) antagonism, even after ischemia, is a helpful strategy to prevent AKI.
In this study, we characterized a model of CKD induced by a single episode of ischemic AKI and the molecular mechanisms that lead to the development of CKD. Our data reveal that spironolactone administration before or after the ischemic insult is a useful strategy to prevent or reduce the development of CKD. RESULTS We have previously shown that, after 24 h of bilateral ischemia, rats develop severe renal dysfunction and tubular injury. 16 Figure 1 shows that renal dysfunction induced by ischemia was completely resolved after 9 days of reperfusion, similar to conditions that often occur in clinical settings. Urinary protein excretion was significantly elevated after 24 h of reperfusion in rats subjected to ischemia and continues to progressively decline until normal values were reached after 6 days of reperfusion ( Figure 1a ). Proteinuria in spironolactone-pretreated rats was 50% lower than the proteinuria in the untreated group, and normal levels were reached faster. Consequently, the rats undergoing ischemia recovered renal function after 10 days, as demonstrated by normal values of renal blood flow, serum creatinine, and creatinine clearance (Figure 1b-d) . Despite the complete improvement in renal function, interleukin (IL)-6 mRNA and phosphorylated Smad3 levels were significantly higher than those in the shamoperated group. Cytokine upregulation was not observed in spironolactone-pretreated rats (Figure 1e -f). These results suggest that although renal function recovered, proinflammatory and profibrotic pathways remained active. These pathways may be able to perpetuate renal injury, which can lead to CKD, a situation that did not occur in spironolactone-pretreated animals.
Ischemic insult leads to progressive renal dysfunction that can be prevented with spironolactone pretreatment
We assessed whether an AKI episode induced by ischemia leads to CKD. Because we have previously shown that I/R injury is prevented by spironolactone pretreatment or adrenal gland removal, 16, 17 we evaluated whether spironolactone pretreatment before ischemia also prevents CKD development. There was considerable mortality in the A-to-C group in the first 10 days after ischemia (57%), and survival was markedly improved by spironolactone pretreatment (15%) (Figure 2a ). Proteinuria was assessed every 30 days. The animals that survived the ischemic insult developed a progressive increase in proteinuria, from 20.2 ± 1.5 mg/day at 30 days to 164.8±11.3 mg/day at 270 days. This increase was not observed in the A-to-C þ Sp group (9.2±1.0 mg/day at 30 days and 27.1±2.0 mg/day at 270 days) ( Figure 2b ). Despite the similar body weights of all rats at the beginning of the study, the A-to-C group exhibited a lower average body weight at the end of the study (583 ± 16.3 g) than did the S, Sp, and A-to-C þ Sp groups (752 ± 28.3, 729 ± 19.2, and 721 ± 11.8 g, respectively). After 9 months, the A-to-C group developed renal dysfunction that was characterized by a significant reduction in renal blood flow and creatinine clearance (Figure 2c and d) . Interestingly, the A-to-C þ Sp group failed to develop renal dysfunction. As shown in Figure 2e , at the end of the study, the mean arterial pressure was similar among the groups. Therefore, the renal injury observed in the rats that developed CKD was not due to hypertension. In agreement with these findings, the rats that developed CKD exhibited an increase in the levels of urinary kidney injury molecule-1, an effect that was not observed in the A-to-C þ Sp group (Figure 2f ).
Ischemic insult leads to severe renal structural injury: prevention by spironolactone pretreatment
Representative light microscopy sections from rat kidneys stained with periodic acid-Schiff are shown in Figure 3a Rats undergoing ischemia exhibited severe structural alterations characterized by glomerular hypertrophy, glomerulosclerosis, cast formation, severe tubular dilation, and tubulointerstitial fibrosis. By contrast, the A-to-C þ Sp group exhibited glomerular and tubular architecture similar to that of control rats. These findings were corroborated by quantification of the number of dilated tubules, percentage of glomerulosclerosis, and glomerular diameter size ( Figures  3 and 4 ). Tubular dilation was present in 42.3 ± 5.0% of the total tubules in the A-to-C group, whereas only 13.1±2.7% of the A-to-C þ Sp group displayed dilation (Po0.01).
Similarly, the A-to-C group exhibited a significantly higher glomerulosclerosis percentage (10.0±4.4%) than the S and A-to-C þ Sp groups (0% and 0.4 ± 0.4%, respectively). The degree of glomerular hypertrophy was evaluated by measuring glomerulus diameter and by generating a distribution of glomerular size. Figure 4a shows the normal diameter distribution of the control group, wherein most of the glomeruli were in the range of 101-125 mm (38.3%), and only a minor proportion was found in the ranges of 76-100 mm (19.5%) and 126-150 mm (27.5%). The histogram for the control group exhibits a typical bell-shaped Gaussian distribution, as we have shown previously. 21 By contrast, in the A-to-C group, the glomerular diameter distribution was shifted to the right, reflecting glomerular hypertrophy. Accordingly, 43.3% of the glomeruli were 4151 mm in diameter. In addition, a lower proportion of glomeruli were found in the diameter ranges of 101-125 mm (20.4%), 76-100 mm (8.3%), and 50-75 mm (0%). All of these differences were statistically significant according to contingency analysis, as shown in Figure 4b . The glomerular size distribution of the A-to-C þ Sp group was similar to that of the control group, but not to that of the A-to-C group (Figure 4c ), indicating that glomerular hypertrophy was nearly absent. In agreement with these findings, renal hypertrophy in the A-to-C group was also evidenced by a significant elevation in the mean kidney weight (2.5±0.2 g) compared with the S and Sp groups (1.6 ± 0.1 and 1.6 ± 0.1 g, respectively); this increase was not observed in the A-to-C þ Sp group (1.5 ± 0.1 g).
Transmission electron microscopy of rat kidneys with CKD revealed ultrastructural alterations that included microvillus degeneration and effacement and detachment of podocyte foot processes ( Figure 4e ). These alterations were rarely observed in the A-to-C þ Sp group (Figure 4f ). Furthermore, an extensive tubulointerstitial area was affected by fibrosis in the A-to-C group (Figure 5a and b), but a lower extent of fibrosis was observed in the A-to-C þ Sp group (Figure 5c and d) . These observations were confirmed by the morphometric analysis represented in Figure 5e . The A-to-C group exhibited fibrosis in 44.8±16.0% of the tubulointerstitial area, compared with 18.7±4.5% in the A-to-C þ Sp group; this difference was significant.
Tubular dilation is due in part to cellular proliferation
To determine whether the severe tubular dilation observed in the A-to-C group was associated with tubular cell proliferation, immunohistochemical analysis of proliferating cell nuclear antigen (PCNA) was performed. The A-to-C group exhibited considerable tubular cell proliferation as demostrated by the number of PCNA þ cells, an effect that was almost absent in the A-to-C þ Sp group (Figure 6a -c). These findings were confirmed by calculating the percentage of nuclei that stained positive for PCNA ( Figure 6d ). The positive cells were primarily located in the dilated tubules, suggesting that enhanced cell proliferation is promoting tubular dilation in the A-to-C group. This assumption is also supported by a significant correlation between the percentage of dilated tubules and the percentage of PCNA þ cells (Figure 6e, r 2 ¼ 0.87).
Tubulointerstitial fibrosis is mediated by TGF-b pathway activation
The role of the tumor growth factor (TGF)-b pathway in promoting tubulointerstitial fibrosis was also evaluated. The A-to-C group exhibited a significant twofold elevation in TGF-b mRNA levels. This increase was not observed in the A-to-C þ Sp group (Figure 7a ). To assess whether this pathway was efficiently activated, the renal levels of downstream effectors of the TGF-b pathway, including phosphorylated Smad3, fibronectin, collagen I, and a-smooth muscle actin (a-SMA), were measured by western blot analysis as shown in Figure 7b -f. The levels of all of these proteins were significantly elevated in the rats that developed CKD. Intriguingly, the activation of the TGF-b pathway was completely prevented in the A-to-C þ Sp group. Recent studies have shown that when Smad2 is phosphorylated, it can act as an antifibrotic modulator of the TGF-b pathway. 23 We found that the A-to-C þ Sp group, which exhibited less tubulointerstitial fibrosis, also displayed a significant elevation in phospho-Smad2 levels.
Renal injury induced by an ischemic insult is also mediated by increased oxidative stress A-to-C þ Sp group. No differences in glutathione peroxidase activity were observed among the groups (Figure 8c ).
Inflammatory cytokine upregulation is involved in ischemia-induced CKD
Tumor necrosis factor alpha (TNF-a), monocyte chemotactic protein-1 (MCP-1), and IL-6 mRNA and protein levels were assessed by real-time reverse transcription-polymerase chain reaction and enzyme-linked immunosorbent assay, respectively. As shown in Figure 9 , the mRNA levels of these cytokines were upregulated in the A-to-C group by 1.6-fold for TNF-a and more than 13-fold for MCP-1 and IL-6, compared with the S group. By contrast, the A-to-C þ Sp group exhibited mRNA levels similar to the control group. These observations were corroborated at the protein level; a similar pattern was observed in the enzyme-linked immunosorbent assay results.
CKD induced by AKI was also reduced by spironolactone administration after the ischemic insult Spironolactone administered at 0 or 1.5 h after the ischemic insult prevented the development of proteinuria compared with the untreated A-to-C group either at low or high doses (Figure 10a and d) . A low dose of spironolactone administered 3 h after ischemia was unable to prevent, but did significantly reduce, the progressive elevation of proteinuria ( Figure 10a ). These findings were not associated with significant changes in renal blood flow (Figure 10b and e) or creatinine clearance (Figure 10c and f), probably because 3 months is an early stage of the CKD, often exhibiting proteinuria, without renal dysfunction, as was observed after a longer period of observation after similar ischemia (Figure 2 ). Despite the lack of significant differences among these groups, spironolactone-treated animals exhibited better renal function than the ischemic group.
At 3 months after inducing bilateral renal ischemia, the untreated A-to-C group, compared with the sham-operated group, exhibited morphological alterations, such as tubular dilation, cast formation, glomerular hypertrophy, and extensive tubulointerstitial fibrosis (Supplementary Figure S1 online). All of these changes were reduced in the animals treated with a low dose of spironolactone (Supplementary Figure S2 online) and were prevented in animals treated with a high dose of spironolactone ( Supplementary Figure S3 online). In fact, glomerular hypertrophy (measured as the distribution of glomerular diameters) was prevented in the groups that received a low dose of spironolactone at 0 h ( Figure 11c ) or high dose at either 0 or 1.5 h after renal bilateral ischemia (Figure 11f and g, respectively). Although kidney changes were not completely prevented, these renoprotective effects of spironolactone were also observed with a low dose at 1.5 and 3 h after ischemia (Figure 11d and e, respectively). Morphometric analyses demonstrated that, 3 months after inducing ischemia, the untreated rats exhibited fibrotic damage in 33.3% of their tubulointerstitium compared with damage in 3.7% of the tubulointerstitium in the sham-operated rats ( Supplementary Figure S1 online) . In contrast, a low dose of spironolactone administered either at 0 and 1.5 h post ischemia reduced the tubulointerstitial fibrosis to 14.8% and 15.1%, respectively, and the 3-h administration reduced the fibrosis to a lesser extent, 20.9% ( Supplementary Figure S2 online) . A high dose of spironolactone at 0 or 1.5 h post ischemia was more effective in reducing the area affected by tubulointerstitial fibrosis to 11.8% and 7.8%, respectively (Supplementary Figure S3 online). Molecular markers of renal fibrosis and inflammation also provided evidence of the protection conferred by spironolactone. The upregulation of TGF-b mRNA levels was prevented or reduced by a low or high dose of spironolactone administered at 0 or 1.5 h after ischemia (Figure 12a and e). However, increased phospho-Smad3 levels remained elevated in rats treated with a low dose, but not with a high dose, of spironolactone (Figure 12b and f) . The renoprotective effect of spironolactone was also associated with the prevention of a-SMA and MCP-1 upregulation (Figure 12c-h ).
DISCUSSION
In this study, we characterized a rat model of CKD induced by a single episode of AKI. We observed that an episode of AKI was resolved in surviving animals within a period of 10 days. However, although physiological parameters returned to normal values, activation of proinflammatory and profibrotic signals persisted. During the following months, progressive deterioration of renal function and renal structures was observed in rats surviving AKI, leading to the development of CKD. Thus, this model resembles what is currently believed to occur in the clinical setting. [11] [12] [13] [24] [25] [26] [27] Patients who survive an episode of AKI and apparently recover renal function may develop CKD later in life. 8, 24 In this study, we observed that spironolactone administration before or after the ischemic insult prevented or significantly diminished the severity of an AKI episode, without signs of proinflammatory or profibrotic activation after 10 days of ischemia. Thus, spironolactone pretreatment resulted in a reduction in rat mortality and in the prevention of CKD. These observations demonstrate the relevance of the prevention of AKI episodes to a reduction in the prevalence of CKD.
CKD development in rats surviving AKI was characterized by a progressive increase in urinary protein excretion, renal dysfunction, glomerular hypertrophy, severe tubular dilation, tubulointerstitial fibrosis, and podocyte injury. Our study supports the hypothesis that an ischemic insult is sufficient to lead to progressive CKD in the rat, despite apparent recovery from the AKI episode. Because it was possible that CKD resulted from irreversible renal artery damage caused by the clamping, a group of rats was studied after 10 days of ischemia, confirming that this was not the case. After 10 days, renal function returned to normal values. Although renal histopathology was not analyzed at this point, we have previously reported that after 3 days of I/R, the tubular epithelium had almost recovered its normal structure. 28, 29 However, in this study, we found that profibrotic and inflammatory cytokines remained at high levels despite a return to normal renal function values. In addition, cytokines such as TNF-a and IL-1b, IL-6, IL-12, IL-15, IL-18, and IL-32 are known to be induced as a result of the enhanced leukocyte activation and leukocyte-endothelial adhesion observed after I/R. Moreover, the renal tubular epithelium may generate proinflammatory cytokines such as TNF-a, IL-6, IL-1b, and TGF-b. [30] [31] [32] [33] It is important to note that Basile et al. 34, 35 and Hörbelt et al. 36 have demonstrated a persistent reduction in vascular density after I/R that maintains a continuous hypoxic and inflammatory state. Furthermore, Conger et al. 37 demonstrated that the postischemic kidney does not properly autoregulate the blood flow. All of these adverse conditions perpetuate continuous cycles of hypoxic damage and inflammation that injure the surrounding tissues and eventually lead to CKD, as has been clearly discussed by Bedfoord et al. 38 In agreement with all these findings, we found that, after 9 months, the rats that developed CKD exhibited greater levels of the proinflammatory cytokines compared with the rats that were pretreated with spironolactone. Interestingly, MCP-1 upregulation observed 3 months after ischemia was also prevented when spironolactone was administered after the insult. Our results suggest that the beneficial results of spironolactone in preventing chronic inflammation are a result of its ability to attenuate I/R-induced acute inflammation.
The CKD induced by an AKI episode was characterized by a progressive enhancement in urinary protein excretion and renal dysfunction without changes in mean arterial pressure. These conditions provide us with an experimental model that dissects the detrimental effect of an AKI episode on renal function and structure without changes in blood pressure. Accordingly, the animals that suffered CKD exhibited severe structural injury. Glomerular hypertrophy and glomerulosclerosis were observed 9 months after inducing ischemia. These alterations were also associated with ultrastructural changes. It is plausible that this glomerular injury is a consequence of the endothelial injury and the endothelial-tomesenchymal transition that occurred after the ischemia. 34, 35 Interestingly, in this study, we found that spironolactone administration both before and after renal ischemia prevented the transition of AKI to CKD. Aldosterone binding to the MR has been suggested to influence endothelial function and vascular tone. 17, 19, 39, 40 Supporting this finding, mice overexpressing MR in the endothelium exhibit altered vascular tone, 40 and aortic wall thickness has been reported in patients with primary hyperaldosteronism. 41 Consistent with this result, aldosterone infusion in mice reduces the expression of glucose-6-phosphate dehydrogenase (G6PDH), a key enzyme in maintaining the balance between nitric oxide and reactive oxygen species production. 42 Therefore, aldosterone has been proposed as a risk factor of vascular injury. 43 The mechanisms involved, however, have not been clearly elucidated. In this regard, we have previously demonstrated that MR antagonism precludes the characteristic hypoperfusion and oxidative stress induced by I/R, suggesting that aldosterone has a pivotal role in mediating renal dysfunction. 16, 22 It is possible that the endothelium and the renal plasma flow of spironolactonetreated rats in this study was minimally affected as a consequence of the I/R injury; therefore, the glomerular structure remained unaffected in the long term.
Tubulointerstitial fibrosis is a common feature of CKD progression (for a review, see Rodriguez-Iturbe and Garcia 44 ). In fact, severe tubular dilation and an extensive area affected by tubulointerstitial fibrosis were found in the A-to-C group. These results suggest that the tubulointerstitium is more susceptible to the effects of an AKI episode and contributes to the progression and severity of CKD in rats suffering from AKI. Accordingly, the severity of tubular damage reportedly exhibits a more significant correlation with the reduction in creatinine clearance than with glomerular injury scores. 45, 46 These tubular defects were associated with an increase in tubular cell proliferation, as demonstrated by the significant increase in PCNA þ staining and by the strong correlation with tubular dilation (r 2 ¼ 0.87). In this study, however, the location of PCNA þ cells in the epithelium of the dilated tubules strongly suggests that the tubular dilation observed in the A-to-C group was mediated in part by uncontrolled tubular cell proliferation triggered during the regeneration process after the ischemic insult. Although a previous study proposed that the increase in cellular proliferation is a necessary process to regenerate tubular epithelium in a period that typically is completed within 4 weeks after ischemia, 47 recent evidence demonstrated that ischemic, nephrotoxic, and obstructive injuries to the kidney induce a G2/M cell cycle arrest in the proximal tubular epithelial cells, sustaining proliferation indefinitely. 48 In this regard, Wynn 49 has proposed that this cell cycle arrest converts normal epithelial cells to a phenotype that promotes the growth and activation of fibroblasts, turning-on the fibrotic process after an ischemic insult. In addition, TGF-b has been recognized as a key mediator of the genesis of renal fibrosis. 32, 50 TGF-b also contributes to the fibrogenesis through inducing epigenetic modifications in fibroblasts in a process that includes the hypermethylation of the gene encoding RASAL1 by the methyltransferase Dnmt1. 51 Accordingly, we found that tubulointerstitial fibrosis developed in the A-to-C group and was associated with increased expression and activation of TGF-b, as evidenced by increases in phospho-Smad3 and its target ECM proteins. Interestingly, activation of the TGF-b signaling pathway was not observed in the animals treated with spironolactone before or after (high dose) ischemia. These data highlight the contribution of TGF-b in mediating renal fibrosis after an ischemic insult. Although Smad2 and Smad3 interact and mediate TGF-b signaling, one recent line of evidence has shown that phospho-Smad2 may act as an antifibrotic effector of the TGF-b pathway. 23 In agreement with those results, the renoprotection conferred by spironolactone was associated with increased levels of phospho-Smad2. The epithelial-to-mesenchymal transition has been suggested to promote tubulointerstitial fibrosis. 52, 53 Under pathological conditions, tubular cells may dedifferentiate into myofibroblasts. TGF-b appears to promote this process by activating the Smad, ILK, and ERK pathways, as observed in tubular cells. 53 To monitor epithelial-to-mesenchymal transition, a-SMA protein levels were measured in the kidney. As expected, the renal fibrosis observed in the A-to-C group was associated with increased a-SMA protein levels. CKD progression has also been linked to an imbalance in free-radical production and antioxidant defense. 44, 54 We confirmed that the rats that developed CKD exhibited greater urinary H 2 O 2 excretion and a reduction in catalase activity. These changes in a-SMA levels and antioxidant factors were not observed in the A-to-C þ Sp group.
In summary, we characterized an experimental model of CKD induced by AKI in the rat. Several mechanisms were responsible for CKD development, including increased tubular cell proliferation, increased TGF-b pathway activation and oxidative stress, and overexpression of proinflammatory cytokines. By using this model of CKD, we demonstrated that the prevention of AKI with spironolactone completely prevents the progression to CKD. Moreover, we also demonstrate that administering an MR blocker after the ischemic insult also prevented CKD. Our results suggest that the treatment of patients with spironolactone after an AKI episode could be of help in preventing the development of CKD.
MATERIALS AND METHODS
All experiments involving animals were conducted in accordance with the Guide for the Care and Use of Laboratory Animals (National Academy Press, Washington, DC, 1996) and were approved by the Animal Care and Use Committee at our Institution.
Protocol 1
In all, 62 male Wistar (weighing 270-300 g) rats were divided into four groups: (1) rats subjected to sham surgery, n ¼ 9 (S); (2) rats treated with spironolactone at 20 mg/kg per day by gastric gavage 3 days before sham surgery, n ¼ 9 (Sp); (3) rats undergoing bilateral ischemia for 45 min, n ¼ 28 (A-to-C); and (4) rats that received spironolactone 3 days before bilateral ischemia, n ¼ 13 (A-to-C þ Sp). All animals were observed for 9 months. In addition, four rats from the S, A-to-C, and A-to-C þ Sp groups were included and observed for 10 days. All animals were kept in a 12:12 h day-night cycle and with free access to water and food.
Protocol 2
Because we recently demonstrated that postischemia MR blockade is beneficial in the prevention of AKI, with the best renoprotection observed in the first 3 h after ischemia, 22 this set of experiments was designed to evaluate whether postischemia spironolactone administration confers protection against the development of CKD. In all, 33 male Wistar (270-315 g) rats were divided into seven groups: sham-operated rats (S); rats subjected to bilateral renal ischemia for 45 min (A-C); and five groups of rats that underwent bilateral renal ischemia for 45 min, but also received one dose of spironolactone at 20 mg/kg by gastric gavage at 0, 1.5, or 3 h after ischemia (A-to-C, 0 h; A-to-C, 1.5 h; and A-to-C, 3 h, respectively), or that received a higher dose of spironolactone (80 mg/kg) at 0 or 1.5 h after ischemia (A-to-C 80, 0 h and A-to-C 80, 1.5 h). These animals were followed up for 3 months. All other methods are described in the Supplementary Materials online.
Statistical analysis
The results are presented as the mean ± s.e. The significance of the differences between the groups was assessed by analysis of variance (ANOVA) using the Bonferroni correction for multiple comparisons. All of the comparisons passed the normality test. The differences in the ranks of glomerular diameters among the groups were evaluated by contingency analysis, and the differences were assessed using the w 2 test with the Yates correction. Statistical significance was defined as P-value o0.05.
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